ATAD2: a new target to treat advanced prostate cancer
Official title: Testing ATAD2 as a new therapeutic target for advanced prostate cancer
Funded at University of California Los Angeles · NIH-11361088 · Data updated 2026-11-12
A new approach targets a protein called ATAD2 to help treat advanced prostate cancer, especially forms that resist standard therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,658,632 |
| NIH project number | 4R01CA287669-03 |
| Project ID | NIH-11361088 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable in this pre-clinical grant; future patients would be those with advanced prostate cancer who might benefit from ATAD2-targeted therapies.
✕Less likely to help
Patients with non-prostate cancers or early-stage disease may not benefit from this specific ATAD2-focused strategy.
What this research studies
This project focuses on advanced prostate cancer, including castration-resistant and neuroendocrine forms, and tests ATAD2 inhibitors in pre-clinical models. Researchers will use cancer cell lines and animal-like models to see if blocking ATAD2 slows tumor growth or works better with other treatments. The goal is to uncover how ATAD2 drives cancer progression and how to best combine inhibitors for effective therapy.
Why it matters
Potential benefit: If successful, this work could lead to new treatments for men with aggressive, treatment-resistant prostate cancer.
How similar studies have gone: Pre-clinical studies have shown ATAD2 inhibitors can suppress NEPC-like tumor growth in models, supporting further development.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Stoyanova, Tanya I — University of California Los Angeles
- Study coordinator: Stoyanova, Tanya I
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.